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The purpose of this study was to evaluate the role and timing of
serial 18F-FDG PET scans as routine surveillance for detecting
early locoregional recurrence, distant metastases, and second
primary tumors in patients treated for advanced squamous cell
carcinoma (SCC) in the oral cavity or oropharynx during the first
year after completion of their curative treatment. Methods:
Forty-eight consecutive patients with SCC in the oral cavity or
oropharynx were included after completing their initial therapy
with curative intent. Prospective follow-up of the participants
was 2-fold: regular follow-up (history and physical examination)
and serial 18F-FDG PET scans. Patients underwent standard fol-
low-up and 18F-FDG PET at 3, 6, 9, and 12 mo after initial treat-
ment. Findings were validated by histopathology or 18 mo of
clinical follow-up and imaging after initial treatment. Results: In-
cidence of recurrences and second primary tumors was 27%
and 10%, respectively. 18F-FDG PET was significantly (P 5
0.035) more often in agreement with the gold standard than
was regular follow-up. 18F-FDG PET showed a sensitivity, spec-
ificity, positive predictive value, and negative predictive value of
100%, 43%, 51%, and 100%, respectively. For regular follow-
up, these values were 0%, 60%, 0%, and 50%, respectively.
18F-FDGPET accounted for a change in diagnostics or treatment
in 63% of the patients and regular follow-up in 25% of the pa-
tients. Sensitivity and specificity of 18F-FDG PET were both irre-
spective of timing of 18F-FDG PET. For the 3- and 6-mo
posttherapy results combined, 18F-FDG PET detected malig-
nancy in 16of the 18patients.Conclusion: 18F-FDGPET is a suit-
able routine posttreatment surveillance tool in oral and
oropharyngeal SCCpatients and detectsmalignancy before clin-
ical suggestion by the regular follow-up arises. The best timing of
a systematic 18F-FDG PET scan is between 3 and 6 mo after
treatment.
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Despite aggressive combined-modality treatment regi-
mens with curative intent (surgery or radiotherapy or
chemotherapy), the locoregional recurrence rate in ad-
vanced head and neck squamous cell carcinoma (HNSCC)
remains high, up to 45% of the patients (1). Most
recurrences occur within the first 2 y after treatment (2).
The initial stage of the tumor has been shown to affect the
recurrence rate, with stages III and IV having an increased
recurrence risk as compared with stages I and II (3). Distant
metastases are less frequently occurring, but nevertheless
they are reported in approximately 5%210% of the
HNSCC patients. Oropharyngeal squamous cell carcinoma
(SCC) more regularly gives rise to distant metastases than
SCC from the oral cavity (4). In addition, the risk of a new
primary cancer developing in these patients is significantly
increased and increases with time (5,6).
In the cases for which tumor recurrence is identified, it is
often beyond the stage of salvation. Curative salvage
treatment of recurrences and treatment of second primary
tumors are possible only if lesions are small and the salvage
treatment that is needed is not limited by the earlier
performed therapy. Early recognition of recurrent disease
and second primary tumors during thorough follow up may
allow early salvage treatment and may potentially confer
a survival advantage (7).
Effective posttreatment surveillance of HNSCC recur-
rence is a diagnostic challenge. Postoperative and post-
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radiation changes in the normal tissues may obscure the
early detection of recurrence, when conventional follow-up
approaches such as clinical assessment, CT, MRI, and
endoscopic examination are applied. 18F-FDG PET offers
a tool that enables the early detection of HNSCC re-
currences. 18F-FDG PET can distinguish recurrent HNSCC
from posttreatment changes and is more effective in
detecting recurrent tumors than physical examination, CT,
or MRI (8–13). However, in most of these studies, the
objective was to assess the ability of 18F-FDG PET to
visualize a recurrence that was clinically already highly
suspected.
18F-FDG PET as a sequential diagnostic tool, indepen-
dent of whether recurrence is suggested, has been in-
vestigated to limited extent. Most of the studies available
evaluated the ability of 18F-FDG PET to assess the response
of the primary tumor and nodal metastases to radiotherapy
or chemotherapy within 2 mo after therapy (14–18). The
impact of 18F-FDG PET on subsequent management may
be different when searching for cancer recurrence rather
than for tumor response. Currently, no consensus exists
regarding interval and frequency of PET scans for surveil-
lance of recurrence in HNSCC in subclinical patients after
treatment.
The purpose of this study was to evaluate the role and
timing of 18F-FDG PET scans as a routine surveillance tool
for detecting early tumor recurrence, distant metastases,
and second primary tumors in patients treated for advanced




This prospective study was conducted at the University Medical
Center Groningen and the Medical Center Leeuwarden, The
Netherlands. Consecutive patients who had been treated curatively
for an advanced (stage III and IV) SCC of the oral cavity or
oropharynx were included after completion of their treatment
(T0). The patients had to complete a follow-up of at least 18 mo
after T0. Not eligible for inclusion were patients treated with
palliative intent or without control of disease after treatment.
The study was conducted according to the Dutch Medical
Research Involving Human Subjects Act, after approval by the
Institutional Review Boards of the participating hospitals. All
patients gave written informed consent to participate in the study.
Follow-up Protocol
The study was set up as a nonrandomized paired design.
Patients served as their own control (i.e., comparison of PET
screening [test] vs. results of regular follow-up [control]). After
the patient completed initial therapy, the follow-up of the
participant was 2-fold: regular follow-up and serial 18F-FDG PET.
The regular follow-up consisted of history and physical
examination at 3-mo intervals at the outpatient department
(OPD). The examination included inspection or palpation of all
anatomic subsites of the head and neck and an examination of
internal structures. Earlier visits to the OPD than scheduled,
because of patients’ complaints, were considered as a part of the
regular follow-up. The outcome of regular follow-up was consid-
ered positive on the basis of symptoms or physical signs
suggestive of a recurrence or second primary tumor during clinical
examination. The clinician had to note if recurrence was sug-
gested. During this assessment, the clinician was unaware of the
outcome of the current 18F-FDG PET results.
Besides this regular follow-up, all patients underwent serial
18F-FDG PET investigations at set times (3, 6, 9, and 12 mo) after
the completion of initial therapy. 18F-FDG PET was planned on
the same day as regular follow-up visits to the OPD.
In the case of negative results of the regular follow-up and
serial 18F-FDG PET, no action was planned and a standard follow-
up protocol was continued. The study finished 18 mo after T0,
leaving a 6-mo observation time after the last PET study.
When local and regional recurrences, distant metastasis, or
a second primary tumor were suggested by either regular follow-
up or 18F-FDG PET, specific additional diagnostics were per-
formed for confirmation, such as CT, endoscopy, biopsy, cytology,
or ultrasound. For any suggestion outside the head and neck area,
the patient was referred to the evaluation consultant of the relevant
specialty. If a recurrence or a second primary tumor was
confirmed by the additional diagnostics, patients were scheduled
for palliative or curative therapy.
The outcome of either biopsy or additional diagnostic pro-
cedures was the gold standard to compare with positive results of
regular follow-up or a 18F-FDG PET scan.
18F-FDG PET Acquisition and Interpretation
All patients had to fast for at least 5 h before undergoing 18F-
FDG PET. 18F-FDG was administered intravenously (4–5 MBq/
kg). After an uptake period of 90 min, PET emission data were
acquired from halfway up the femur to the skull base. Two devices
were used: an ECAT EXACT HR 1 scanner (Siemens CTI),
which acquires 63 planes over 15.5 cm, and a Biograph 6 PET/CT
scanner (Siemens), which acquires 81 planes over 16.2 cm. The
measured resolution of both systems is 4–5 mm in full width at
half maximum transaxially in the center of the field of view. On
both systems, attenuation-corrected images were obtained, either
from low-dose CT data or from a 68Ge/68Ga ring source. CT
images were used for attenuation correction only.
Two nuclear medicine physicians, both experienced in PET,
visually evaluated all PET images independently. They were
unaware of the findings of the current regular follow-up.
In the case of a second, third, or fourth scan, the nuclear
medicine physicians had access to all available clinical data at the
time of previous scans, including the results of the previous
regular follow-up and of morphologic imaging but not of the
regular follow-up at the time of the current scan. The level of
confidence in image interpretation was graded using a 5-point
grading system (0, definitely no tumor; 1, probably no tumor; 2,
equivocal; 3, probably tumor; and 4, definite tumor). On a case
record form, the results of each scan were divided into 3 regions:
primary, neck, and distant. In the final analysis, grades 2, 3, and 4
were considered positive. In the case of discrepancies, consensus
was aimed for. If no consensus could be reached, a third in-
dependent nuclear medicine physician made the final assessment.
Impact of PET on Patient Management
If a recurrence or second primary tumor was suggested by
regular follow-up or 18F-FDG PET, or both, a new diagnostic
strategy was applied to the patient. The extent to which 18F-FDG
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PET and regular follow-up led to changes in management was
compared. If the recurrence or second primary could be confirmed
within the study period, the change in management was consid-
ered to have been appropriate; otherwise, it was considered to
have been superfluous.
The number of detected recurrences or second primary tumors
by 18F-FDG PET and the regular follow-up were compared and
treatment strategies were assessed.
Statistics
A sample size of 40 patients was initially planned. It was
estimated that 40% of the patients would have recurrences or
second primary tumors. Assuming that 18F-FDG PET had a sen-
sitivity of 80% or 90%, the corresponding 95% confidence
intervals would be 57%293% or 71%299%, respectively. Drop-
out was estimated at 20% of all included patients; consequently,
48 patients were required.
Sensitivity, specificity, and negative and positive predictive
value of 18F-FDG PET and regular follow-up were calculated on
the basis of comparison with the gold standard or with a minimal
6-mo relapse-free time after PET 4 (which refers to PET
performed at 12 mo after therapy) with no evidence of malignancy.
Calculations were performed at patient level and scan level for
each of the 3 regions separately. The diagnostic value of 18F-FDG
PET was compared with that of regular follow-up. At the patient
level, comparison was performed by means of the McNemar test.
Confidence intervals (95%) of the difference in outcomes were
calculated using confidence interval analysis. Proportional ob-




Between February 2006 and May 2007, 48 patients were
enrolled in the study. All patients (32 men, 16 women) were
available for data analysis. Their mean age was 59.96 9.7 y.
Tumor characteristics and treatment modalities are listed in
Table 1. A reconstruction was performed in 21 patients:
split-thickness skin grafts, 8; free radial forearm flaps, 7;
free fibula flaps, 5; and pectoralis major flap, 1.
Locoregional recurrences, distant metastases, or a second
primary tumor after a median follow-up of 7.2 mo
(interquartile range, 4.8–13.2) developed in 18 patients
(Table 2). During the study, 16 patients died after a median
period of 1.6 y (interquartile range, 0.7–1.9 y) after treat-
ment; 15 deaths were due to malignancy, and 1 was due to
cardiac arrest.
18F-FDG PET Findings
Patient Level. Serial 18F-FDG PET identified all re-
currences, distant metastases, or second primary tumors
that occurred within the observation period of 18 mo. The
regular follow-up detected none at the particular time point
yet (Table 2). 18F-FDG PET results were false-positive in
19 patients on 1 or more occasions. Regular follow-up
results were false-positive in 12 patients. In 5 of these
patients, 18F-FDG PET results were also false-positive. The
difference between 18F-FDG PET and regular follow-up is
significant (P 5 0.035). Table 3 summarizes the diagnostic
properties of 18F-FDG PET and regular follow-up. In 10 of
18 patients with a true-positive PET result, diagnostic
modalities were capable of confirming the disease directly.
In 8 patients, it took at least 3 mo to confirm the diagnosis
(Table 2; Fig. 1).
Scan Level. In the follow-up period of the study pop-
ulation, 156 scans were performed. All 48 patients un-
derwent a PET scan 3 mo after treatment, 40 patients after
6 mo, 35 patients after 9 mo, and 33 patients after 12 mo.
In Table 4, the diagnostic properties of the serial 18F-
FDG PET scans are shown. Overall, 18F-FDG PET showed
a high sensitivity and a high negative predictive value.
Because of substantial false-positive results, specificity and
positive predictive value were considerably lower. Between
different anatomic sites (head, neck, and distant), no
significant differences were found.
The 35 18F-FDG PET scans that were rated false-positive
showed a false-positive hot spot at 38 anatomic sites, 20 of
which were local, 6 were regional, 6 were distant, 2 were
both local and distant, and 1 was both regional and distant.
In addition to these 35 false-positive scans, 1 patient
underwent 2 scans, with a true-positive spot in the
oropharynx but also a false-positive result for the lung
due to an encapsulated fungal infection. Consequently,
thirty-seven 18F-FDG PET scans showed 40 false-positive
results. In 24 of the 40 (60%) false-positive results, clear
(nonmalignant) anatomic substrates, of which the nuclear
physicians were not aware at the time of their analysis
because clinical data was masked and CT data were not
used, were present (Table 5). Correcting for this effect
improved specificity and positive predictive value greatly,
as shown in Table 4 (data given in parentheses). In 9























Surgery and radiotherapy 33
Chemoradiation 5
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patients, the false-positive results had resolved on the next
18F-FDG PET scans. For the remaining false-positive scan
results, the false-positive hot spots were present on 2 scans
minimally. Three patients showed false-positive hot spots in
all 4 scans (Fig. 2), 2 of which were located locoregionally
and 1 in the lung.
Proportional observer agreement for detecting malig-
nancy was 0.88, and Cohen k was 0.75. Per anatomic site,
agreement and Cohen k were 0.87 and 0.65, 0.92 and 0.56,
and 0.90 and 0.69, respectively, for the primary site, neck,
and distant sites.
Impact of 18F-FDG PET. At the patient level, 18F-FDG
PET induced changes in diagnostic procedures or treatment
in 63% of the patients, whereas regular follow-up did in
25%. However, the change by 18F-FDG PET or regular
follow-up led in 40% and 100% to superfluous diagnostic
procedures, respectively—that is, procedures that were
performed because of a false-positive result.
In all 18 patients with recurrences or second primary
tumors, additional diagnostic procedures for confirmation
were initiated by 18F-FDG PET; the regular follow-up
initiated none. Seven of the 18 patients (39%) received
a curative salvage treatment. Three of these 7 patients died
(mean 6 SD, 9.5 6 2.4 mo) after salvage treatment,
because of recurrences; 4 are still alive, without signs of
malignancy. The other 11 patients received palliative
treatment (Table 2).
In 2 patients, 18F-FDG PET led to overtreatment: in 1
patient, lung cancer was suggested by 18F-FDG PET and
was confirmed by CT. This patient underwent a lobectomy,
but histopathology showed an encapsulated fungal infection.
The other patient underwent a neck dissection because of
a wrong localization of a local recurrence by 18F-FDG PET.
Timing of 18F-FDG PET Scans. Table 6 shows 18F-FDG
PET performances at each time (3, 6, 9, and 12 mo after
treatment). Diagnostic properties did not show significant
differences among the scans. In 14 of the 18 patients (78%)
with disease detected by serial 18F-FDG PET, the disease
was recognized on the 3-mo posttreatment scan. Eight were
confirmed by additional diagnostic procedures at that time,
and 6 patients needed 1 or more diagnostic procedures after
PET scans and additional diagnostic procedures to confirm
the diagnosis. 18F-FDG PET 3 and 6 mo after therapy
detected malignancy in 16 of the 18 patients, including all

























1 OC T4N2c CR Recurrence Local 1 Histopathology Direct Salvage surgery
2 OC T4N0 SR Recurrence Local 1 Histopathology Direct Palliative
3 OP T4N2c CR Recurrence Local 1 Histopathology Direct Palliative
radiation
4 OP T2N2b R Recurrence Local 1 Histopathology Direct PDT
5 OC T3N2b SR Recurrence Local, pelvic bone 1 Histopathology,
MRI
Direct Palliative
6 OP T3N0 SR Recurrence Local 1, 2, 4 Histopathology 9 Palliative
7 OC T2N2b SR Recurrence Local, neck 1, 2 Histopathology,
USFNAC
3 Palliative
8 OC T1N2b SR Recurrence Neck 1, 2 USFNAC 3 Salvage
surgery/radiation
9 OP T4N2b SR Recurrence Local, neck, lung 1 CT Direct Palliative
10 OP T4N2c CR Recurrence Local, neck, lung 1 CT Direct Palliative
11 OC T4N2c SR Recurrence Local, lung, kidney 1, 2, 3, 4 CT, USFNAC 9 Palliative
12 OP T2N2c R Recurrence Lung/esophagus 2, 3, 4 Histopathology, CT 18 Palliative
13 OC T4N1 CR Recurrence Lung 1 CT Direct Palliative
14 OC T4N0 SR Second PMT Esophagus 1, 2 Histopathology 3 Palliative
15 OC T4N2c SR Second PMT Lung T4N0 3 Histopathology Direct Lobectomy
16 OC T4N0 SR Second PMT Lung T3N0 2, 3 Histopathology 3 Lobectomy
17 OC T3N1 SR Second PMT Lung T1N0 4 Histopathology Direct Lobectomy
18 OC T3N0 SR Second PMT Lung T1N0 1, 2 Histopathology 3 Lobectomy
*PET 1, 2, 3, and 4 refer to PET performed at 3, 6, 9, and 12 mo after therapy, respectively.
yDiagnosis of recurrence or second primary tumor was based on histopathology, or if histopathology was not available, on clinical
follow-up and imaging.
zTime of diagnosis confirmation in months after first suggestion by PET return. For patient 6, PET 3 was cancelled because of
rehabilitation after lobectomy, and for patient 11, PET 4 also detected carcinoma of kidney.
OC5 oral cavity; CR5 chemoradiation; SR5 combination of surgery and radiotherapy; OP 5 oropharynx; R 5 radiotherapy; PDT5
photodynamic therapy; USFNAC 5 ultrasound-guided fine-needle aspiration cytology; PMT 5 primary tumor.
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recurrences. 18F-FDG PET results 9 and 12 mo after
treatment were in most patients a confirmation of malig-
nancy detected by previously performed PET scans.
DISCUSSION
There is a high risk that recurrences, distant metastases,
and second primary tumors will develop in patients treated
for advanced HNSCC of the oral cavity and oropharynx and
will compromise their survival. In the current study, a re-
currence rate (local, regional, and distant) of 27% (13
patients) was shown. In 5 patients (10%), a second primary
tumor developed. Early identification may allow early
treatment with curative intent and may potentially confer
a survival advantage (7). We could prove, because of the
paired design of the current study, that 18F-FDG PET
detects malignancy before clinical suggestion by the
regular follow-up occurs during the 1-y follow-up of
patients treated for SCC of the oral cavity or oropharynx.
Moreover, none of the recurrences and simultaneous second
primary tumors was detected by the regular follow-up, and
all were detected by 18F-FDG PET.
Currently, there is no consensus regarding the interval
and frequency of 18F-FDG PET scans in the follow-up of
HNSCC patients. There were several reasons why we chose
to perform the first 18F-FDG PET study at 3 mo after
treatment. 18F-FDG PET performed within 10 wk after
radiation or chemoradiation has been associated with high
rates of false-negative findings due to a time period of
decreased 18F-FDG uptake after chemoradiation, despite
the ongoing presence of viable tumor cells (19). False-
positive findings, which are attributed to nonspecific
mucosal changes due to chemoradiation, are also associated
with 18F-FDG PET performed too early after treatment
(20). In addition, the efficacy of chemoradiotherapy (the
tumor-kill phenomenon) cannot be fully assessed for at
least 8–10 wk after completing chemoradiation. When 18F-
FDG PET is performed within 2 mo after treatment, the
indication is to evaluate the response to chemoradiation
rather than search for recurrences. Moreover, locoregional
recurrences, after combined therapeutic modalities includ-
ing conservative surgery, usually occur later. 18F-FDG PET
performed as a sequential investigation 4 mo after treat-
ment, independent of whether recurrence is suggested,
showed high accuracy (12,14,21,22). However, recurrences
could also be apparent clinically or radiographically at the
time of PET. Performing the first sequential PET study at
3 mo after treatment resulted in a high sensitivity and
detection rate before other clinical indications were appar-
ent. Similarly, the negative predictive value of 18F-FDG
PET was high, in accordance with other studies in which
18F-FDG PET was performed at 12 wk or more after
therapy, encouraging an early onset of reconstruction if
indicated in case of negative scan findings (23,24).
Few systematic prospective studies have been conducted
in which the use of repeated routine posttreatment 18F-FDG
PET in a heterogeneous group of HNSCC patients was
tested (14,21,25). Because of the study design of repeating
scans (every 3 mo), we were able to investigate efficacy and
optimum timing of posttreatment 18F-FDG PET scans.
Sensitivity and specificity of 18F-FDG PET were not
dependent on timing in the 3- to 12-mo posttreatment
surveillance (Table 6). 18F-FDG PET at 3 mo detected all
recurrences except 1 (Table 2) and induced the greatest
change in nonsuperfluous diagnostic strategy. PET 1 and 2
detected malignancy in 16 of the 18 patients and thus, 18F-
FDG PET performed at 3–6 mo after therapy, in accordance
FIGURE 1. Transaxial 18F-FDG PET/
CT images of recurrence with contralat-
eral cervical metastasis. (A) A 3-mo
posttreatment 18F-FDG PET image sug-
gestive of local recurrence, not con-
firmed by physical examination, biopsy,
and ultrasound. (B) A 6-mo posttreat-
ment 18F-FDG PET image showing in-
creased 18F-FDG uptake and additional
contralateral 18F-FDG focus, confirmed
by CT.
TABLE 3. 18F-FDG PET and Regular Follow-up Performances at Patient Level
Modality TP FN TN FP Sensitivity Specificity PPV NPV Accuracy
18F-FDG PET 18* — 13 17 100%y 43% 51%y 100%y 65%y
Regular follow-up — 18 18 12 0% 60% — 50% 38%
*In 2 patients, 18F-FDG PET showed both true- and false-positive results.
ySignificant difference between 18F-FDG PET and regular follow-up using 95% confidence interval analysis.
TP 5 true-positive; FN 5 false-negative; TN 5 true-negative; FP 5 false-positive; PPV 5 positive predictive value; NPV 5 negative
predictive value.
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with the findings of a retrospective study by Lee et al. (26),
was the best timing for imaging after treatment. In 2
studies, systematic 18F-FDG PET/CT showed a high accu-
racy at 12 mo after treatment (27,28). However, the authors
suggested a higher impact of 18F-FDG PET at 6 mo after
treatment, because the 18F-FDG PET at 12 mo after
treatment had significantly less impact than did earlier
performed 18F-FDG PET motivated by clinical suspicion
(27). Their suggestion was indeed proven by our results.
Another study performed routinely 18F-FDG PET/CT about
12 mo after therapy, but with a large SD (positive PET/CT
and negative PET/CT results, 10.7 6 4.7 and 12.3 6 4.1
mo, respectively) (28).
What is unclear is whether a follow-up 18F-FDG PET scan
after a previous systematic 18F-FDG PET scan is indicated
and which time interval has to be used. A retrospective study
on timing of 18F-FDG PET suggested that locoregional
recurrences are unlikely for at least 1 y after initial negative
18F-FDG PET scans (26). Although the impact of a second
18F-FDG PET scan would be significantly less than that of the
first systematic 18F-FDG PET scan, it might be appropriate to
perform a second PET scan 1 y after the first systematic 18F-
FDG PET scan, knowing that in our study 3 second primary
tumors and 1 recurrence not detected by the first 18F-FDG
PET scan would have been detected at that time point.
A limitation of 18F-FDG PET was its low specificity and
positive predictive value. For reasons of screening, a high
false-positive risk is more easily accepted as long as
sensitivity approaches 100% and false-positive results do
not increase the risk of patient morbidity. 18F-FDG PET
seems to fulfill these criteria in the current study. Many
false-positive scans were related to distinct pathologic
lesions other than SCC (Table 5) and in fact were
recognized by clinical assessment or other imaging tech-
niques (but were unavailable to the nuclear physician
because of the design of the study). However, discrimina-
tion between 18F-FDG uptake caused by SCC or by other
pathologic lesions is impossible for nuclear medicine
physicians unaware of clinical information, and malignancy
will be suspected first until proven otherwise. Paradoxi-
cally, patients treated for advanced SCC are at high risk for
high 18F-FDG uptake both by SCC and by nonneoplastic
causes such as mucositis and osteoradionecrosis. In this
respect, PET/CT could reduce false-positive results, as it
allows direct correlation of 18F-FDG uptake with anatomic
structures. PET/CT improves the ability to localize lesions,
decreasing the risk of sampling errors (28–30). Moreover,
anatomic imaging is required to determine which anatomic
structures are involved and to recognize crucial tumor char-
acteristics such as perineural spread, which is related to a poor
prognosis and may alter treatment strategies (31). Because of
the use of 2 different PET cameras in this study, anatomic
information was ignored at first to get a uniform analysis of
the study population. Otherwise, a bias could not be excluded
because of possible differences in performances between PET/
CT and PET fused with separate CT or MRI.
High focal 18F-FDG uptake without a correlating ana-
tomic substrate raises a diagnostic dilemma. In 8 of the 18
patients with true pathologic 18F-FDG uptake, conventional
work-up was not able to confirm the 18F-FDG PET findings
until 3–12 mo later (Table 2; Fig. 1). In contrast, there were
also patients with persistent unexplained 18F-FDG uptake
in subsequent scans that was never confirmed (Fig. 2).
Therefore, positive 18F-FDG PET scans have to be con-
firmed by at least 1 other diagnostic procedure to prevent
overtreatment. Unfortunately, this compromises the intent
TABLE 5. Forty False-Positive Results in 37 Scans with





Second-stage-surgery endosseous implants 3
Warthin tumor 1
Lost endosseous implant with infection 1
Abscess 1
Ulcer maxillary tuberosity 1
Unknown anatomic substrate 12
Distant
Pneumonia 1 costal fracture 2
Clavicular fracture and costal fracture 1
Osteoporotic fracture T8–12 1
Encapsulated fungal infection, lung 2
Infiltration residue 1
Unknown anatomic substrate, lung 3
Unknown anatomic substrate, hilus 1
TABLE 4. Accuracy of 156 Serial 18F-FDG PET Scans in Detecting Persistent, Recurrent, or Metastatic HNSCC Overall
and at Different Anatomic Sites
Area TP FN TN FP Sensitivity Specificity PPV NPV Accuracy
All regions 30 (50) 1 90 35 (15) 97% (98%) 72% (86%) 46% (77%) 99% (99%) 77% (90%)
Head 16 (32) — 118 22 (6) 100% (100%) 84% (95%) 42% (84%) 100% (100%) 86% (96%)
Neck 7 (8) — 142 7 (6) 100% (100%) 95% (96%) 50% (57%) 100% (100%) 96% (96%)
Distant 16 (23) 1 128 11 (4) 94% (96%) 92% (97%) 60% (85%) 99% (99%) 92% (97%)
In parentheses are false-positive results with known pathologic substrates other than malignancy, such as mucositis or fractures, that
were counted as true-positive.
TP 5 true-positive; FN 5 false-negative; TN 5 true-negative; FP 5 false-positive; PPV 5 positive predictive value; NPV 5 negative
predictive value.
18F-FDG PET IN FOLLOW-UP OF HNSCC • Krabbe et al. 1945
to detect recurrences as early as possible. To minimize
false-positive results in routine patient care, we recommend
the following: nuclear medicine physicians should be
informed in detail about clinical history and additional
pathology. If there is no explanation for the positive result
by clinical assessment, other imaging techniques should be
performed. If no anatomic substrate has been found,
frequent follow-up and repeated PET after 3 mo are
recommended. Figure 3 shows a flow diagram. On the
basis of our results, if repeated 18F-FDG PET showed
clearly less or no 18F-FDG uptake, a false-positive result for
the previous PET study is highly likely. However, if the 18F-
FDG uptake was unchanged or increased, discrimination by
18F-FDG PET between true- and false-positive is impossi-
ble and morphologic imaging or biopsy is required.
The early detection of recurrent disease or second primary
tumors may lead to an improved outcome (32,33). However,
despite the early detection, the success rate of salvage
treatment in the current study was low; only 7 (15%)
patients underwent salvage therapy because of serial
18F-FDG PET, of which 4 (8%) remained free of malig-
nancy. It is not surprising that only a small percentage of the
participants could be salvaged, because only a small per-
centage of patients treated for advanced HNSCC who have
a recurrence can be expected to be cured (34). Because the
rate of recurrence is highest in advanced HNSCC, these
patients were included to study PET effectiveness. To pro-
vide data on the impact of systematic 18F-FDG PET on
survival, further studies that include patients with lower-
staged HNSCC are needed.
CONCLUSION
The current study showed that 18F-FDG PET is signif-
icantly more sensitive than regular follow-up for routine
TABLE 6. Performance of 18F-FDG PET Scans 3, 6, 9, and 12 Months After Curative Treatment
Index PET 1 (n 5 48) PET 2 (n 5 40) PET 3 (n 5 35) PET 4 (n 5 33)
True-positives 14 8 4 4
False-positives 9 [4]* 9 [6]* 10 [7]* 7 [3]*
False-negatives 1 — — —
True-negatives 24 23 21 22
Sensitivity 93% 100% 100% 100%
Specificity 73% 72% 68% 76%
PPV 61% 47% 29% 36%
NPV 96% 100% 100% 100%
Accuracy 79% 78% 71% 79%
Change in diagnostic strategy 20/48 (42%) 13/40 (33%) 9/35 (26%) 8/33 (24%)
Superfluous change 7/20 (35%) 6/13 (46%) 7/9 (78%) 4/8 (50%)
Newly detected malignancy 14 2 1 1
Confirmation at time of PET 8 4 2 3
Curative treatment 2 2 2 1
Alive without malignancy 2 0 1 1
*Numbers in brackets are false-positives with known anatomic substrate, nonmalignant.
FIGURE 2. Transaxial 18F-FDG PET
images demonstrated false-positive fo-
cus present during all 4 scans in first
year after treatment, without confirma-
tion by MRI, CT, and follow-up. Here are
shown 3-mo (A) and 12-mo (B) post-
treatment images.
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surveillance of oral and oropharyngeal SCC patients treated
with curative intent. 18F-FDG PET detected all malignancy
before clinical suggestions by the regular follow-up existed.
In 7 patients (15%), early PET diagnosis led to treatment
with curative intent. The impact is highest for 3- and 6-mo
posttreatment PET. Therefore, we recommend 1 systematic
18F-FDG PET 3–6 mo after treatment.
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FIGURE 3. Flow diagram of 18F-FDG PET in HNSCC after
treatment. Diagnostic strategy should be revised after twice-
repeated 18F-FDG PET to prevent infinite 18F-FDG PET
follow-up. neg 5 negative; pos 5 positive.
18F-FDG PET IN FOLLOW-UP OF HNSCC • Krabbe et al. 1947
